The Glasgow Microenvironment Score: an exemplar of contemporary biomarker evolution in colorectal cancer

IF 3.4 2区 医学 Q1 PATHOLOGY
Katrina Knight, Christopher Bigley, Kathryn Pennel, Jennifer Hay, Noori Maka, Donald McMillan, James Park, Campbell Roxburgh, Joanne Edwards
{"title":"The Glasgow Microenvironment Score: an exemplar of contemporary biomarker evolution in colorectal cancer","authors":"Katrina Knight,&nbsp;Christopher Bigley,&nbsp;Kathryn Pennel,&nbsp;Jennifer Hay,&nbsp;Noori Maka,&nbsp;Donald McMillan,&nbsp;James Park,&nbsp;Campbell Roxburgh,&nbsp;Joanne Edwards","doi":"10.1002/2056-4538.12385","DOIUrl":null,"url":null,"abstract":"<p>Colorectal cancer remains a leading cause of mortality worldwide. Significant variation in response to treatment and survival is evident among patients with similar stage disease. Molecular profiling has highlighted the heterogeneity of colorectal cancer but has had limited impact in daily clinical practice. Biomarkers with robust prognostic and therapeutic relevance are urgently required. Ideally, biomarkers would be derived from H&amp;E sections used for routine pathological staging, have reliable sensitivity and specificity, and require minimal additional training. The biomarker targets would capture key pathological features with proven additive prognostic and clinical utility, such as the local inflammatory response and tumour microenvironment. The Glasgow Microenvironment Score (GMS), first described in 2014, combines assessment of peritumoural inflammation at the invasive margin with quantification of tumour stromal content. Using H&amp;E sections, the Klintrup–Mäkinen (KM) grade is determined by qualitative morphological assessment of the peritumoural lymphocytic infiltrate at the invasive margin and tumour stroma percentage (TSP) calculated in a semi-quantitative manner as a percentage of stroma within the visible field. The resulting three prognostic categories have direct clinical relevance: GMS 0 denotes a tumour with a dense inflammatory infiltrate/high KM grade at the invasive margin and improved survival; GMS 1 represents weak inflammatory response and low TSP associated with intermediate survival; and GMS 2 tumours are typified by a weak inflammatory response, high TSP, and inferior survival. The prognostic capacity of the GMS has been widely validated while its potential to guide chemotherapy has been demonstrated in a large phase 3 trial cohort. Here, we detail its journey from conception through validation to clinical translation and outline the future for this promising and practical biomarker.</p>","PeriodicalId":48612,"journal":{"name":"Journal of Pathology Clinical Research","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/2056-4538.12385","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pathology Clinical Research","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/2056-4538.12385","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Colorectal cancer remains a leading cause of mortality worldwide. Significant variation in response to treatment and survival is evident among patients with similar stage disease. Molecular profiling has highlighted the heterogeneity of colorectal cancer but has had limited impact in daily clinical practice. Biomarkers with robust prognostic and therapeutic relevance are urgently required. Ideally, biomarkers would be derived from H&E sections used for routine pathological staging, have reliable sensitivity and specificity, and require minimal additional training. The biomarker targets would capture key pathological features with proven additive prognostic and clinical utility, such as the local inflammatory response and tumour microenvironment. The Glasgow Microenvironment Score (GMS), first described in 2014, combines assessment of peritumoural inflammation at the invasive margin with quantification of tumour stromal content. Using H&E sections, the Klintrup–Mäkinen (KM) grade is determined by qualitative morphological assessment of the peritumoural lymphocytic infiltrate at the invasive margin and tumour stroma percentage (TSP) calculated in a semi-quantitative manner as a percentage of stroma within the visible field. The resulting three prognostic categories have direct clinical relevance: GMS 0 denotes a tumour with a dense inflammatory infiltrate/high KM grade at the invasive margin and improved survival; GMS 1 represents weak inflammatory response and low TSP associated with intermediate survival; and GMS 2 tumours are typified by a weak inflammatory response, high TSP, and inferior survival. The prognostic capacity of the GMS has been widely validated while its potential to guide chemotherapy has been demonstrated in a large phase 3 trial cohort. Here, we detail its journey from conception through validation to clinical translation and outline the future for this promising and practical biomarker.

Abstract Image

格拉斯哥微环境评分:当代结直肠癌生物标志物演变的典范。
结肠直肠癌仍然是全球死亡的主要原因。分期相似的患者对治疗的反应和存活率明显不同。分子图谱分析凸显了结直肠癌的异质性,但对日常临床实践的影响有限。目前急需具有强大预后和治疗相关性的生物标志物。理想的情况是,生物标志物可以从用于常规病理分期的 H&E 切片中提取,具有可靠的灵敏度和特异性,并且只需最低限度的额外培训。生物标志物的目标将捕捉关键的病理特征,这些特征已被证实对预后和临床有用,如局部炎症反应和肿瘤微环境。格拉斯哥微环境评分(GMS)于2014年首次被描述,它将侵袭边缘的瘤周炎症评估与肿瘤基质含量量化相结合。利用H&E切片,通过对浸润边缘瘤周淋巴细胞浸润的定性形态学评估确定克林特鲁普-迈基宁(KM)分级,并以半定量方式计算肿瘤基质百分比(TSP),即可见视野内基质的百分比。由此得出的三个预后类别具有直接的临床意义:GMS 0 表示肿瘤有密集的炎症浸润/浸润边缘有较高的 KM 等级,生存率较高;GMS 1 表示炎症反应较弱,TSP 较低,生存率处于中等水平;GMS 2 表示肿瘤炎症反应较弱,TSP 较高,生存率较低。GMS 的预后能力已得到广泛验证,其指导化疗的潜力已在一项大型三期试验中得到证实。在此,我们将详细介绍它从构想、验证到临床转化的过程,并概述这一前景广阔且实用的生物标记物的未来。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Pathology Clinical Research
Journal of Pathology Clinical Research Medicine-Pathology and Forensic Medicine
CiteScore
7.40
自引率
2.40%
发文量
47
审稿时长
20 weeks
期刊介绍: The Journal of Pathology: Clinical Research and The Journal of Pathology serve as translational bridges between basic biomedical science and clinical medicine with particular emphasis on, but not restricted to, tissue based studies. The focus of The Journal of Pathology: Clinical Research is the publication of studies that illuminate the clinical relevance of research in the broad area of the study of disease. Appropriately powered and validated studies with novel diagnostic, prognostic and predictive significance, and biomarker discover and validation, will be welcomed. Studies with a predominantly mechanistic basis will be more appropriate for the companion Journal of Pathology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信